Connect with us

International

E.U. Reg. Backs Lung Cancer Drug

EUROPE – Astrazeneca said on Friday its cancer drug Enhertu was recommended by the European Medicine Agency’s human medicines committee as a monotherapy to treat patients with a type of non-small cell lung cancer.

Published

1 year ago

on

EUROPE – Astrazeneca said on Friday its cancer drug Enhertu was recommended by the European Medicine Agency’s human medicines committee as a monotherapy to treat patients with a type of non-small cell lung cancer.

The recommendation is based on the mid-stage data that showed Enhertu showed objective response rate of 49%.

The drug is already approved in the European Union as a treatment for patients with an advanced form of breast cancer.

Related Topics:
Comments

Trending